ZEB2 and prostate carcinoma: Overexpression of both ZEB1 and ZEB2 has been reported in a number of cancers, including prostate cancer [44, 45], breast cancer [46], gynecological cancers [47-49], head and neck cancers, and specifically in oral squamous cell carcinoma [29, 50, 51].